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We present an applied study in cancer genomics for integrating
data and inferences from laboratory experiments on cancer cell lines
with observational data obtained from human breast cancer studies.
The biological focus is on improving understanding of transcriptional
responses of tumors to changes in the pH level of the cellular mi-
croenvironment. The statistical focus is on connecting experimentally
defined biomarkers of such responses to clinical outcome in obser-
vational studies of breast cancer patients. Our analysis exemplifies
a general strategy for accomplishing this kind of integration across
contexts. The statistical methodologies employed here draw heav-
ily on Bayesian sparse factor models for identifying, modularizing
and correlating with clinical outcome these signatures of aggregate
changes in gene expression. By projecting patterns of biological re-
sponse linked to specific experimental interventions into observational
studies where such responses may be evidenced via variation in gene
expression across samples, we are able to define biomarkers of clin-
ically relevant physiological states and outcomes that are rooted in
the biology of the original experiment. Through this approach we
identify microenvironment-related prognostic factors capable of pre-
dicting long term survival in two independent breast cancer datasets.
These results suggest possible directions for future laboratory stud-
ies, as well as indicate the potential for therapeutic advances though
targeted disruption of specific pathway components.
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1. Introduction. Cancer progression involves a complex interaction of
genetic and genomic factors that jointly subvert normal cell development.
The genomic component, which encompasses gene expression and regulation,
is substantially impacted by the biochemical composition of the local envi-
ronment in which a cell grows. So-called micro-environmental parameters,
including levels of oxidation, lactate, acidity, nutrients of various kinds and
other factors affecting physical interactions between cells, are increasingly
studied for their potential to improve our understanding of cancer biology,
and for their promise to lead to new therapeutic strategies. Changes in
such parameters can impact gene transcription, which in turn impacts pro-
tein production. Variation in these fundamental parameters can therefore
induce a cascade of effects, producing disruptions of normal cellular pro-
cesses in downstream biological pathways [Hanahan and Weinberg (2000)].
For example, changes to the pH level in the cellular environment may ef-
fect glycolysis, thus impacting on numerous genes involved in the glycolysis
pathway. Some of these genes may also play roles in the regulation of cell
growth, and their suppression may engender tumorigenesis and promote the
aggressive advance of existing cancerous states. Microarray gene expression
assays can be used to generate data on the transcriptional response of can-
cer cells to controlled manipulations of environmental factors such as pH.
This data is useful for characterizing these micro-environmental response
pathways.
Our study concerns changes to cellular pH levels, and the resulting neu-
tralization and lactic acidosis response pathways. Section 2 describes the ap-
plication of sparse Bayesian regression models [Lucas et al. (2006);
Seo, Goldschmidt-Clermont and West (2007)] to microarray data generated
through a series of laboratory experiments on cultured breast tumor cells
in which cellular pH levels were manipulated in a controlled manner. These
analyses yield statistical expression signatures of the cellular responses to
various interventions on the pH level. The main challenge lies in relating
these signatures, and the biological pathways they characterize, to variation
in gene expression across large samples of human breast tumors. This inte-
gration of in vitro and in vivo data sets is the driving focus of this and related
studies. In addition to comprising a detailed study of new data and experi-
mental results, through which are generated several directions for biomedical
research, this work exemplifies an overall strategy for cross-study, integrative
analysis of gene expression data for exploring and relating pathway-related
experimental findings to clinical contexts and patient outcomes.
When considering variability in expression patterns of genes in obser-
vational tumor data, we face questions of differences due to the differing
contexts. It is to be expected that a tumor in vivo evidences far more com-
plex and heterogeneous biological variation than in the controlled in vitro
setting, and this will be manifest in measures of gene expression. Normal cell
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processes held in quiescence in cell cultures may when active co-regulate the
expression of relevant signature genes in in vivo, confounding the pattern of
expression that was evident in vitro. Hence, when aiming to translate ex-
perimental findings to tumor populations, thereby providing a mapping of
an in vitro signature to its in vivo counterpart, we require statistical models
capable of discovering and representing the additional complexity surround-
ing and interacting with the original response signature. Section 3 describes
our analysis of a large and heterogeneous breast cancer data set using sparse
latent factor models [West (2003); Carvalho et al. (2008)] that satisfy these
desiderata. This analysis includes a targeted factor search that facilitates
estimation of statistical factors associated with an initial set of genes under-
lying the in vitro experimental signatures. The factors discovered in this way
represent a modular decomposition of the biological patterns evident in the
in vivo breast cancer data, while retaining connections to the experimental
signatures.
Section 4 discusses aspects of the biological and clinical interpretations
of these estimated factors, which can be viewed as a refined in vivo set of
summary biomarkers of variation in the neutralization and lactic acidosis
response pathways of these breast cancers. In survival analyses, we find that
these factor model derived biomarkers have substantial prognostic value in
connection with long-term survival and, hence, the sets of genes comprising
these factors warrant further study. We present predictive validation of this
key finding in analyses of two separate breast cancer data sets. We then
provide biological interpretation of one key factor that emerged from the
evolutionary factor search, which plays a key role as a predictive variable
in the survival analyses. It turns out that this factor is a single compo-
nent of a specific biological pathway that has previously been noted as a
risk biomarker in cancer, but not, to date, connected at all into response
pathways linked with variation in cellular pH. This finding has generated
follow-on biological research and initiated a new line of experimentation on
the role of this pathway in connection with cancer cell micro-environmental
influences.
2. Neutralization experiments and analysis.
2.1. Biological and experimental context. Investigating the effects of
changes in the micro-environment in which cells grow is of increasing interest
in cancer research. The tumor micro-environment is typically characterized
by oxygen depletion, high lactate and extracellular acidosis coupled with
vascular leakage, glucose and energy deprivation. These and other micro-
environmental features vary widely across tumors and generally exhibit sub-
stantial temporal and spatial differences in a tumor. Micro-environmental
stresses trigger biochemical changes in cancer cells that directly modulate
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Table 1
Summary of neutralization/acidosis experiments. Cell entries indicate the number of
replicates per experimental group
Exposure condition
pH 7.4 pH 6.7 pH 5.5
Growth condition 1hr 4hr 1hr 4hr 4hr
pH 7.4 3× 3× 3× 3× 3×
pH 6.7 3× 3× 3× 3×
physiological, metabolic and ultimately clinical phenotypes. Improved un-
derstanding of the molecular mechanisms of such tumor responses holds
promise for immediate translational impact and clinical care, as relevant
therapies can be brought to bear to modify the micro-environment.
Currently, with the exception of hypoxia, very little is understood about
how each individual stress affects cellular phenotypes and tumor progression.
To examine how cancer cells respond to increased acidity or pH neutraliza-
tion at different time points, MCF7 cell cultures (a commonly-used breast
tumor cell line) were grown in neutral media and then exposed to varying
interventions in several assays in parallel. For some cells, lactic acid was
added to the medium (25 mM lactic acid at pH 6.7) for 1 and 4 hours;
others cells experienced strong lactic acidosis conditions (25 nM lactic acid
at pH 5.5) for 4 hours. Similarly, the effects of neutralization were assayed
by shifting the MCF7 cultures from overnight lactic acidosis conditions at
pH 6.7 to neutral regular media at pH 7.4 for 1 and 4 hours. Control cells
were grown in each starting condition (neutral conditions and lactic acido-
sis conditions). The complete set of experiments is summarized in Table 1.
The mRNA extracted from each of the resulting n = 27 batches of MCF7
cultures was purified using Ambion miRVana RNA purification kits and
standard microarray assays were performed using Affymetrix U133 Plus 2
Genechip platforms. All raw microarray data were preprocessed using RMA
[Irizarry et al. (2003)], the log (base 2) scale output of which were used in
all ensuing statistical analyses.
2.2. Cellular response signatures. Quantitative summaries of the cellu-
lar responses to lactic acidosis and neutralization treatments were obtained
using a standard sparse multivariate regression model [Lucas et al. (2006);
Seo, Goldschmidt-Clermont and West (2007)]. We analyzed 19,375 genes
(technically, probe-sets from the Affymetrix array; we will use “gene” and
“probe” interchangeably) whose median expression level is at least 5.5 and
whose expression ranges more than 0.5-fold across the n= 27 experimental
samples. Let Xexp denote the 19,375× 27 matrix of expression values. Rows
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represent genes and columns correspond to three replicate samples for each
of the following experimental groups: (i) control (pH 7.4→ 7.4) at 1 hour;
(ii) control at 4 hours; (iii) lactic acidosis (pH 7.4→ 6.7) at 1 hour; (iv)
lactic acidosis at 4 hours; (v) neutralization (pH 6.7→ 7.4) at 1 hour; (vi)
neutralization at 4 hours; (vii) acidic growth (constant pH of 6.7) at 1 hour;
(viii) acidic growth at 4 hours; (ix) strong lactic acidosis (pH 7.4→ 5.5) at
4 hours. Let Hexp denote the 11× 27 design matrix where the first 8 rows
contain binary indicators for effects associated with differential expression
relative to the 1hr control group: 1hr lactic acidosis effect, 1hr neutraliza-
tion effect, 1hr acidic growth effect, 4hr control effect, 4hr lactic acidosis
effect (relative to 4hr control), 4hr neutralization (relative to 4hr control),
4hr acidic growth effect (relative to 4hr control) and 4hr strong lactic aci-
dosis effect (relative to 4hr control). The last three rows contain artefact
control factors derived from the first three principle components of the ex-
pression levels associated with the AFFX series control genes included on
the Affymetrix microarrays. These control genes are not variably expressed
in humans, and so patterns of variation across samples manifest in con-
trol genes represents systematic errors arising from different experimental
conditions. Use of these artefact control factors provides opportunity for
sample-specific correction of artefactual effects on genes that may otherwise
result in false-discovery or obscure meaningful biological variation [following
Lucas et al. (2006) and Carvalho et al. (2008)]. After deriving the artefact
control factors, rows corresponding to Affymetrix control genes are removed
from subsequent analyses.
The model for the expression of gene g in sample i is
xexpg,i = µg +
11∑
k=1
βg,kh
exp
k,i + νg,i
or in matrix from
Xexp = µ1 +BH +N,
where µg denotes the mean expression of gene g in the 1hr control sam-
ples, each βg,k is the change in expression of gene g due to design factor k,
and the νg,i are independent, normally distributed idiosyncratic noise terms
representing residual biological variation, experimental and measurement er-
rors with individual variances ψg. Sparsity is induced via prior distributions
that place positive probability on βg,k = 0 for each g, k pair, and result-
ing posterior analysis allows investigation of posterior sparsity patterns via
probabilities pi∗g,k =Pr(βg,k 6= 0|X
exp). Full details follow Lucas et al. (2006)
and prior specifications, including priors for the µk, variance parameters
and all hyper-parameters, are given in Supplement B. Posterior inference
via MCMC is achieved using the BFRM software [Wang et al. (2007)].
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Fig. 1. Neutralization signature skeleton: black indicates genes g (rows) with posterior
probability pi∗g,k > 0.99 for each experimental group k (columns). Genes are ordered to
emphasize which genes are unique to each successive experiment relative to the previous.
Figure 1 broadly illustrates genes uniquely associated with individual
treatment effects as well as those involved in multiple responses. This gives
some indication of the degree of intersection of the cellular pathways being
queried by the different treatments. Across the 8 treatments, the sparsity,
as measured by the percent of genes for which pi∗g,k > 0.99, ranges from 29%
(4 hour neutralization) to 46% (4 hour lactic acidosis). The fold-change as-
sociated with the involved genes (2|βg,k| for g such that pi∗g,k > 0.99) ranges
from 1.06× to 13×, with a mean of 1.4×.
The cellular response to each treatment, also called the signature of the
treatment, is characterized by estimated effects β∗g,k =E(βg,k|βg,k 6= 0,X
exp)
together with the pi∗g,k. The ability of each signature to uniquely identify the
treatment it reflects can be further explored using summary signature scores
as defined in Lucas, Carvalho and West (2009). Based on posterior means
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Fig. 2. Neutralization treatment signature scores (sk,i) for each sample in the original
study. Separate treatment groups are color coded.
β∗g,k and ψ
∗
g , let
sk,i =
19,375∑
g=1
β∗g,kx
exp
g,i /ψ
∗
g
define the score for treatment signature k on sample i. This expression is
derived from the data-driven component of the Bayes factor that weighs
the evidence in favor of the given signature describing the variation in a
sample (p(xi|hk,i = 1)/p(xi|hk,i = 0)). Figure 2 shows the values of the scores
associated with 7 treatment signatures plotted across samples. As expected,
the highest scoring samples for each signature are those upon which that
signature is based, but important connections between signatures can be
identified on the basis of other high- or low-scoring treatment groups. For
example, there is a inverse relationship between the 4hr acidosis score and
the 4hr neutralization score. Also evident is the similarity between the 1hr
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and 4hr acidic growth signatures, which can also be inferred through the
large intersection of the genes defining the two signatures (Figure 1).
3. Latent factor analysis of breast tumor gene expression.
3.1. In vivo breast cancer data. The primary goals of this study are to
uncover shared structures in the cell response signatures defined above, and
to quantify the extent to which these structures can be used to predict
clinical phenotypes in real human cancers. Here we make use of the gene
expression data for a collection of 251 surgically removed breast tumors
as reported in Miller et al. (2005). Affymetrix 133A and 133B GeneChip
microarrays were generated for each tumor sample, and relevant clinico-
pathological variables were collected for each patient. This included age at
diagnosis, tumor size, lymph node status (an indicator of metastatic cancer)
and Elston histological grade (a categorical rating of malignancy as deemed
by pathologists). Molecular assays to identify the presence of absence of
mutations in the estrogen receptor (ER), progesterone receptor (PgR) and
P53 genes were also performed. These data are representative of a variety of
different presentations of human breast cancer on these clinical measures.
We first evaluate the signature score as defined above for each tumor.
These scores are then standardized across samples so that each vector of 27
scores for a particular signature has mean and variance equal to the mean
gene-specific expression and mean gene-specific variance. This transforma-
tion places the signature scores on the same scale as gene expression in the
tumor data set, thus enabling a “metagene” interpretation of a vector of
scores [West et al. (2001); Pittman et al. (2004)]; see Figure 3. The rela-
tionships between the tumor signature scores bear some similarities to those
observed in the cell line study. There is once again evidence of correlation
between the two acidic growth signatures and the 1hr neutralization signa-
ture. These three signatures, in turn, display patterns opposite that of the
4hr neutralization signature. The patterns are less prominent, however, than
was evident in the cell culture data. Although the variation in these scores
presumably relates, in part, to underlying biological variation in the activity
of the lactic acidosis and neutralization response pathways within these tu-
mors, as mentioned above, the set of genes characterizing the in vivo effects
of lactic acidosis and neutralization may differ substantially from those char-
acterizing the in vitro responses as a result of the more complex interactions
with other cellular processes.
We thus aim to refine our evaluation of the response pathway activity
levels in the tumor data by using the signature scores as initial “anchors”
in an analysis using sparse latent factor models. The main idea is to define
statistical factors on sets of genes related to these initial scores, and to link
in other genes that may connect with the different response pathways active
in vivo. This is accomplished as follows.
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Fig. 3. Initial evaluation of neutralization signature levels across tumor samples. Sam-
ples are ordered by first principle component to emphasize dominant signature gradients.
3.2. Sparse factor model specification. Sparse latent factor models rep-
resent common patterns in gene expression via latent factors in which the
factor-gene relationships are sparse; this notion of statistical sparsity
is key for representing the intersecting subsets of genes potentially
related to underlying networks of biological pathways [West (2003);
Seo, Goldschmidt-Clermont and West (2007); Lucas et al. (2009);
Carvalho et al. (2008)]. The form of the statistical model is an extension
of the sparse regression model. A key part of our analysis strategy stems
from augmenting the 44,592×251 matrix of gene expression data for the tu-
mor data with the 7 values of the projected treatment signature scores. Let
p= 44,592 + 7 = 44,599 and n= 251, and let Xobs denote the p× n matrix
in which the first 7 rows are the projected scores across tumor samples, and
rows 8− p are the gene expression values. Here we will make use of K = 4
artefact control factors derived from the first four principal components of
the control genes of the breast tumor microarrays. A latent factor model
consisting of L latent factors is therefore
xobsg,i = µg +
K∑
k=1
αg,kλk,i+
K+L∑
l=K+1
αg,lλl,i+ νg,i
or, in matrix form,
Xobs = µ1 +AΛ+N,
where: (i) the firstK rows of the (K+L)×nmatrix Λ are the known artefact
controls; (ii) the remaining L rows contain latent factor scores; (iii) the first
K columns of the p× (K + L) matrix A are regression parameters on the
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artefact controls (changing notation from the earlier β to α for notational
convenience here); (iv) the remaining L columns of A are factor loadings
parameters relating factors to genes and to the projected scores; and (v) A is
sparse, with sparsity pattern to be inferred along with estimation of nonzero
values. The model is completed by assigning sparsity priors over columns
of A, precisely as was done for B in the sparse regression model; prior
specification for A, variance components and other hyper-parameters follows
default recommendations for the BFRM framework (see Supplement B).
Flexibility in representing potentially complicated patterns underlying ex-
pression is achieved using nonparametric Bayesian Dirichlet process models
for the factor scores. The L-vectors (λK+1,i, . . . , λK+L,i)
′, representing the
latent factor values on tumor sample i, are modeled as draws from an un-
known latent factor distribution subject to a Dirichlet process prior with
a multivariate normal base measure. This standard nonparametric mixture
model allows great flexibility in adapting to nonnormal structures commonly
manifest in factor scores [Carvalho et al. (2008); Wang et al. (2007)].
Ensuring the identifiability of latent factors requires the use of a modified
prior on A such that the leading L rows have an upper triangle of zeros and
positive upper diagonal elements; that is, for g = 1 :L, we have αg,g+K > 0
and αg,l = 0 for l > g + K. The first L variables in X
obs then represent
“founders” of the L latent factors, with variable g associated with a αg,g-
fold change in expression due to factor g, (g = 1, . . . ,L). It also defines an
hierarchical dependence on the factors, namely,
xobs1,i = · · ·+ α1,K+1λK+1,i+ ν1,i,
xobs2,i = · · ·+ α2,K+1λK+1,i+α2,K+2λK+2,i+ ν2,i,
xobs3,i = · · ·+ α3,K+1λK+1,i+α3,K+2λK+2,i+α3,K+3λK+3,i+ ν3,i
and so on. This structure aids the interpretation of the latent factor load-
ings as representing interconnected components of a complex biological pro-
cess. The latent factor scores λi,l quantify variation across tumors for these
expanding levels of complexity, with each additional factor accounting for
variation in observed gene expression unaccounted for by the previous set
of factors. With our use of projected in vitro signature scores here as the
first 7 variables, the first 7 factors will now represent patterns underlying
co-variation in expression of sets of genes that link indirectly to these treat-
ment signatures. Additional factors then reflect other dimensions of common
variation in the set of genes analyzed.
3.3. Targeted factor search. Decomposition of the patterns of variation
evident in the tumor gene expression data into latent factors proceeds through
evolutionary model search, full details of which appear in Carvalho et al.
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(2008) and Wang et al. (2007). The evolutionary model search provides a
computationally efficient approximation to the computationally prohibitive
full factor analysis on the entire set of genes, and produces full posterior
results for the final set of factors and genes. A key novelty of this approach
is that we exploit the sensitivity of the model search procedure to its ini-
tial configuration in order to explore the space of factor models surrounding
an initial model containing 7 latent factors and representing only the 7 re-
sponse metagenes. By construction, these initial factors are each defined, or
“founded,” by the neutralization/lactic acidosis treatment scores, thereby
ensuring that the model search is primarily concerned with patterns of vari-
ation related to these particular response pathways.
Evolution of this initial model proceeds as follows. Samples from the joint
posterior distribution of model parameters are obtained through MCMC.
Based on these fitted values, we impute inferences for all genes g > 7 that are
not currently included in the model, as described in Carvalho et al. (2008).
Thus, after fitting the initial factor model which considers only the signa-
ture scores, we examine expression levels of the full set of 44,000+ genes
for evidence of association with the current factors. The imputation pro-
cess generates approximate probabilities pi∗g,l =Pr(αg,l 6= 0|X
obs) for all such
genes g. Genes are ranked on the basis of these probabilities, and the model
is then expanded to include a small number of the genes with largest values
of the projected pi∗g,l. The model is then refitted to this expanded sample,
and if appropriate, the number of factors is increased in order to adapt to
additional common patterns of expression variation now evident in the in-
creased set of variables being modeled. This process is repeated until no new
genes or factors can be added, or until the model reaches a designated maxi-
mum size. More details on the search strategy, including control parameters
governing model expansion, are given in Supplement B.
The initial 7-gene, 7-factor model evolved under this process to reach a
terminal size of 500 variables (the designated maximum) incorporating 30
latent factors. Figure 4 shows the skeleton of the factor structure, in terms
of major patterns of gene-factor relationships. The ordering of the factors is
determined by the model search procedure, and represents the incremental
improvement to model fit provided by each subsequent factor. In this sense,
each subsequent factor builds upon the complexity modeled by the previous
factors. The leading 7 factors correspond to the following signatures, respec-
tively: 4hr lactic acidosis, 1hr lactic acidosis, 1hr neutralization, 4hr strong
lactic acidosis, 4hr acidic growth, 1hr acidic growth, and 4hr neutralization.
Like their in vitro signature counterparts, the in vivo factors loadings con-
tain a great deal of sparsity. Of the 493 genes included in the final model,
only 333 are among those identified in the in vitro signature analysis. Factor
1, founded by the the 4hr lactic acidosis signature score, has 173 genes with
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Fig. 4. Skeleton of fitted factor loadings for tumor data. Black indicates variable-factor
loadings with pi∗g,l > 0.99. The first 7 variables are the projected neutralization scores, fol-
lowed by 493 genes reordered for a clear visual presentation of the sparsity structure of,
and cross-talk in, gene-factor loadings.
nonzero loadings at the 0.99 probability threshold, compared to 8909 in the
in vitro signature.
Posterior estimates of the factor loadings (α∗g,l = E(αg,l|αg,l 6= 0,X
obs))
aid in generating further insights. In particular, the upper portion of the es-
timated loadings matrix sheds light on the structure of connections between
latent factors; see Figure 5. As described in Section 3.2, one interpretation
of a row A is as a set of coefficients determining a linear combination of
factor scores that predict the gene expression vector for the corresponding
variable. The inset of Figure 5 shows that the fitted values of all 7 of sig-
nature scores involve positive contributions from factor 1, the factor version
of the 4hr lactic acidosis signature. Thus, the pattern of 4hr lactic acidosis
signature activity across samples describes a fundamental pattern of path-
way activation that underlies the activity patterns of the other 6 signatures.
The seventh factor (i.e., the factor representation of the 4hr neutralization
signature) sits atop this hierarchy of pathway complexity, represented as a
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Fig. 5. Heat map showing the magnitudes of the fitted factor loadings α∗g,l for the first
L= 30 rows of A. The founder gene for each factor is designated by its U133+ probe ID.
The terms in each row determine a linear combination of latent factors that predict the
observed expression levels of the founder gene.
linear combination of factors 1 (4hr neutralization), 3 (1hr neutralization),
4 (4hr strong lactic acidosis) and 5 (4hr acidic growth), plus the additional
pattern of expression unique to this pathway.
4. Biomedical connections of factor profiles.
4.1. Factor-based prediction of long term survival. The in vivo latent fac-
tors linked to neutralization pathways represent complexity in the patterns
of expression, and therefore in the levels of underlying biological pathway
activation evident across the tumor samples. For this reason, latent factors
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can be regarded as candidate biomarkers of physiological states that link
to these pathways. Our study explores this using the posterior mean factor
scores λ∗l,i as candidate predictors in a survival analysis of the breast cancer
patient data.
We use Weibull regression models of patient survival that draw on the
30 estimated neutralization/lactic acidosis pathway factors, the 7 original
projected signature scores and the clinical covariates available for this data
set [Miller et al. (2005)]. The latter include histologic grade, ER mutation
status, node status, P53 mutation status, PgR mutation status, tumor size
and age at diagnosis. This analysis allows both integration and comparison
of the prognostic value of these traditional markers with specific pathway-
related signature scores, and their latent factor representations—an inte-
grative clinico-genomic analysis. Let ti denote the survival time of patient
i. The Weibull density function is p(ti|a, γ) = at
a−1
i exp(ηi − t
a
i e
ηi), where
a > 0 is the index parameter and ηi = γ
′yi the linear predictor based on a
covariate vector yi.We explore subsets of covariates and regression model un-
certainty using Bayesian shotgun stochastic search [Hans, Dobra and West
(2007); Hans et al. (2007b)]. This generates a list of regression covariate sub-
sets and the corresponding posterior regression model probabilities for use in
Bayesian model averaging for survival prediction and in exploring relevance
of variables. Details of model and prior specification follow defaults in the
SSS software [Hans et al. (2007b)] as noted in Supplement B.
Figure 6 shows posterior probabilities for each of the 46 candidate covari-
ates. Nodal status emerges as the leading predictor of long term survival,
followed by latent factor 30 and then tumor size. Note that none of the
original signature scores, and no other clinical variables, receive apprecia-
ble probability. That nodal status provides the best predictor of survival is
to be expected. Previous studies [West et al. (2001); Pittman et al. (2004);
Dressman et al. (2006)] have shown that nodal status is not well predicted
by gene expression and that combined use of nodal status with gene ex-
pression predictors can improve survival prognosis. Hence, it seems that the
information content of the nodal status predictor is unlikely to overlap with
that of any factor score. This can also be clearly seen through the pairwise
inclusion probabilities in Figure 7.
The pairwise inclusion probability of factor 30 and nodal status is close
to the marginal probability of factor 30; however, the pairwise inclusion
probability of factor 30 with any of the other factors is far less than any
of the marginal inclusions probabilities of those factors; thus, factor 30 is
clearly a dominant and preferred expression-based biomarker of survival risk.
Posterior and predictive inferences are formally based on a mixture of 1000
Weibull survival models, mixed with respect to their posterior probabilities.
For each patient i, we can compute the implied predicted survival function
at her covariate vector yi and identify the predicted median survival mi;
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Fig. 6. Posterior inclusion probabilities for the 46 candidate covariates in the Weibull
models. The candidate covariates include the 30 estimated latent factors, followed by the
7 original signature scores, followed by 10 traditional clinical covariates (Elston grades 1,
2 and 3, ER, node status, P53, PgR status, tumor size, age at diagnosis).
this is the predicted median survival time for a future patient who has the
same covariates as patient i. Figure 8(a) shows a Kaplan–Meier survival
plot of the Miller et al. data simply stratified by mi ≤m or mi >m, where
Fig. 7. Pairwise inclusion probabilities for the top 6 predictor variables in breast cancer
survival analysis. Darker colored tiles indicate higher probabilities.
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Fig. 8. (a) Kaplan–Meier curves demonstrating stratification of Miller data into high-
and low- risk groups, based on the fitted Weibull mixture. (b) Estimated survival curve
associated with varying levels of factor 30, holding all other predictors at their median
values. (c) Kaplan–Meier curves demonstrating stratification of Miller data into high- and
low- risk groups, based solely on the value of factor 30.
m = median{mi, i = 1, . . . , n}. There is approximately a 30% difference in
the empirical 10-year survival probability between patients cohorts stratified
crudely on this basis, as a simple visual of the relevance of the included
covariates. By way of focusing on factor 30, we plot the model-averaged
survival curve for a hypothetical patient whose covariates are held constant
at their median values in the data set, save for variation in the factor 30 score;
BAYESIAN FACTOR ANALYSES IN INTEGRATIVE CANCER BIOLOGY 17
see Figure 8(b), where factor 30 is set at its 5th, 50th and 95th percentiles
in the data set, all other covariates remaining fixed. The estimated effect of
variation in factor 30 alone accounts for approximately 20% of the difference
in 10-year patient survival between the high-risk and low-risk subgroups.
This prediction is confirmed by considering the Kaplan–Meier curves formed
by stratifying the patients on the basis of the patient-specific factor 30 value
compared to the median across samples; see Figure 8(c). The pattern of gene
expression comprising the loading associated with factor 30 warrants further
investigation, to which we will return in Section 4.3.
4.2. Out-of-sample factor projection. It is critical to evaluate whether
or not the above results can be confirmed through out-of-sample prediction.
We do this with two additional breast cancer data sets: that of Pawitan et al.
(2005), consisting of 159 primary breast tumors assayed on Affymetrix U133A
and U133B chips, and that of Sotiriou et al. (2006), consisting of 189 pri-
mary breast tumors assayed on U133A chips.
Fixing all factor model parameters at their posterior means, we can di-
rectly predict values of the latent factors for each new patient; see
Supplement B and [Lucas et al. (2009)]. Note that this calculation is purely
predictive; no model fitting nor additional analysis of the two validation
data sets was performed. Using the predicted latent factor vectors, we can
produce the same survival plots for these data, stratifying each of the two
Fig. 9. Kaplan–Meier curves demonstrating stratification of (a) the Pawitan et al.
(2005) patient samples, and (b) the Sotiriou et al. (2006) patient samples (right) into
high- and low- risk groups based on imputed values of factor 30, as identified in the latent
factor analysis of the Miller data.
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Fig. 10. Predicted values of factors 1 and 30 for each sample in the original experimental
study. Separate treatment groups are color coded.
new patient cohorts on the basis of their factor 30 scores as above; see Figure
9, as compared to Figure 8(c). The association between low factor 30 scores
and good prognosis remains evident in these out-of-sample predictions that
draw on different patient populations. Further, the differences between high
and low risk groups is comparable across all three samples.
The robustness of factor 30 as a prognostic biomarker provides strong
support for the view that it reflects a biologically meaningful module of
gene expression. By evaluating the predicted factor scores in the original
experimental data, we are able to establish that factor 30, despite its rela-
tively late incorporation to the model, is linked to the 4-hour lactic acidosis
pathway. Figure 10 compares the predicted factor scores for factors 1 and
30 as evaluated in the experimental data. Factor 1, which is founded by
the 4-hour lactic acidosis signature, is in fact comparable to the original
signature score as depicted in Figure 2. Factor 30 has its highest values in
the original 4-hour lactic acidosis samples, but shows a different pattern of
activity across the other sample cohorts. In particular, factor 30 appears to
be repressed in the samples associated with the 4-hour neutralization and
acidic growth treatments. This implies that factor 30 may characterize some
critical intersection between these pathways that is itself related to tumor
aggressiveness.
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4.3. Biological evaluation of prognostic factor 30. Having established the
clinical relevance of factor 30, the task remains to ascribe to it biological
meaning. The loading of factor 30 is comprised of only 6 gene probe sets for
which pi∗g,l > 0.99. Four of these, including the founder gene, are related to
the phosphoglycerate kinase 1 (PGK1) gene, while the other two are related
to a neuronal cell death-related protein and the CEGP1 protein. The factor
is characterized by overexpression (βg,k > 0) of the PGK1 and neuronal cell
death proteins and suppression (βg,k < 0) of CEGP1.
A literature search generates detailed biological information on PGK1,
and its role in the glycolysis pathway where it is fundamental to cell
growth and metabolism. PGK1 catalyzes the reversible conversion of
1,3-diphosphoglycerate to 3-phosphoglycerate with the generation of one
molecule of ATP and this represents an important step in glycolysis path-
ways. In addition, PGK1 has been reported to induce other processes related
to cancer progression, such as conferring a multi-drug resistant (MDR) phe-
notype [Duan et al. (2002)] and affecting tumor angiogenesis through affect-
ing secreted plasmin [Lay et al. (2000)]. Previous studies have also shown
that elevated levels of PGK1 predict poor survival outcomes in lung cancers
[Chen et al. (2003)], and that PGK1 can often be expressed at high levels
in pancreatic [Hwang et al. (2006)] and renal [Unwin et al. (2003)] cancers.
The association between high factor 30 levels and poor prognosis indicates a
similar relationship between PGK1 and survival may exist for breast cancers.
Since PGK1 is an important component of glycolysis pathways, our find-
ings here may implicate glycolysis activities in poor patient survival. This
is supported by previous findings that expression of glycolysis pathways
and PGK1 are repressed by lactic acidosis [Chen et al. (2008)]. Factor 30
links the neutralization pathway response signatures to a clear PGK1 factor
that may now serve as a biomarker of one key aspect of tumor responses to
changes in pH with the potential to aid in predicting follow-on changes in tu-
mor metabolism via glycolysis pathway activation. Further evaluation of this
chain of relationships is now initiated and will be explored using indepen-
dent methods such as tumor tissue microarrays [Chen et al. (2003)]. Since
PGK1 and glycolysis pathways are also controlled by hypoxia [Chi et al.
(2006)], these results also highlight their potential roles as integral media-
tors of multiple micro-environmental factors affecting tumor progression and
clinical outcomes.
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SUPPLEMENTARY MATERIAL
Supplement A: Software and Data (DOI: 10.1214/09-AOAS261SUPPA;
url). This site contains all materials needed to reproduce the reported analy-
ses. This includes all data files, control files for the BFRM and SSS software,
and MATLAB functions for producing graphical summaries.
Supplement B: Appendix (DOI: 10.1214/09-AOAS261SUPPB; .pdf). The
appendix Merl et al. (2009) provides further details on prior specifications
in the sparse regression and sparse latent factor models. The appendix also
contains details on the control parameters for the evolutionary factor search
and shotgun stochastic search, and describes the procedure for imputing
factor scores in new samples.
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